<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77163">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01796145</url>
  </required_header>
  <id_info>
    <org_study_id>HCC033</org_study_id>
    <nct_id>NCT01796145</nct_id>
  </id_info>
  <brief_title>Fibroscan Study in HCC</brief_title>
  <official_title>A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with inoperable HCC undergoing non-surgical therapy as first-line therapy

        1. We aim to determine the prognostic significance of liver stiffness in patients with HCC

        2. We aim to determine the rate and severity of complications of treatment and its
           association with liver stiffness in patients with HCC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and grade of treatment complications</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness (kPa)</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Confirmed Diagnosis of HCC;</condition>
  <condition>Patients Who Are Scheduled to Undergo TACE or Systemic Therapy;</condition>
  <condition>Child's A or B Cirrhosis.</condition>
  <arm_group>
    <arm_group_label>TACE or Systemic Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TACE or Systemic Therapy</intervention_name>
    <arm_group_label>TACE or Systemic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of inoperable HCC

          -  Patients who are scheduled to undergo non-surgical therapy, either TACE or systemic
             therapy

               1. For TACE cohort, patients undergoing first cycle TACE are eligible.

               2. For systemic therapy cohort, patients undergoing first-line systemic therapy are
                  eligible.

          -  Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave,
             percutaneous ethanol injection) is allowed

          -  Child's A or Child's B liver function

        Exclusion Criteria:

          -  Child's C liver function

          -  ECOG performance status &gt; 2

          -  Poorly controlled ascites
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Lam Chan, FHKCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Lam Chan, FHKCP</last_name>
    <phone>2632 1042</phone>
    <email>l_chan@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherlaine YAU, RN</last_name>
    <phone>2632 1138</phone>
    <email>sherlaine@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Lam Chan, FHKCP</last_name>
      <phone>2632 1042</phone>
      <email>l_chan@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Sherlaine Yau, RN</last_name>
      <phone>2632 1138</phone>
      <email>sherlaine@clo.cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Lam Chan, FHKCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
